四環醫藥(00460.HK)旗下軒竹生物與美國HB公司合作開發新型靶向蛋白降解技術
格隆匯8月13日丨四環醫藥(00460.HK)發佈公吿，集團旗下軒竹生物科技有限公司與美國HB Therapeutics, Inc.(“HB公司”)同意合作，雙方將針對新型靶向蛋白降解技術展開合作開發。軒竹生物將向HB公司支付預付款及特定里程碑付款，在選定的開發藥物進入到臨牀前候選化合物階段後， HB公司有權獲得額外里程碑付款。軒竹生物將擁有合作項目在大中華區的開發、生產及商業化權益。
根據披露，靶向蛋白降解(TPD)是一種新興的治療手段，它代表了一個革命性的藥物發現機會，並預計將為現代醫學的發展帶來革命性轉變。靶向蛋白降解的作用原理是利用小分子配體來重定向細胞蛋白穩態機制。這種新興靶向蛋白降解技術將藥物發現從功能性抑制劑轉變為目標蛋白的蛋白降解劑。通過利用泛素蛋白體系統(UPS)，招募E3泛素化連接酶來降解，從而去除致病蛋白。該平台可以發現新的藥物並用於治療多種實體瘤和神經退行性等疾病。
HB公司是一家位於美國印地安納州的新興的生物醫學公司，專注於發現和開發針對致病蛋白的小分子蛋白降解劑，以開發抗腫瘤及抗衰老等領域的“First-in-Class”原創新藥。 HB公司開發的“基於細胞篩選的新型靶向蛋白降解技術”，通過發現特定蛋白的小分子降解物和識別靶向的新型E3連接酶複合物，可用於開發各種致病蛋白的分子膠降解劑(Molecular glue degraders)。作為一項新興的藥物發現平台方法，該技術可以用於降解更多難以成藥的靶點，拓展可成藥的蛋白靶點庫，為後續研發分子膠形式的新靶點創新藥物奠定基礎，也使治癒更多種類的疾病成為可能。
公吿表示，軒竹生物擬與HB公司共同合作，引進HB公司的藥物發現及篩選技術平台，共同開發三個創新的分子膠蛋白降解藥物並獲得產品未來在大中華地區的開發及商業化權益，從而進一步加強軒竹生物在新藥研發領域的科技水平，提升行業競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
